Folosim cookie-uri pentru a îmbunătăți experiența pe site. Pentru detalii, citește Politica de confidențialitate.

Wegovy and Ozempic maker forecasts sharp drop in revenue for 2026

04.02.2026 12:51 | The Guardian World

Novo Nordisk share price plunges after blaming lower US drug prices, patent protection issues and rising competition The maker of Wegovy and Ozempic, Novo Nordisk, has predicted a sharp drop in revenues this year owing to a push by Donald Trump to lower US weight-loss drug prices, rising competition and the loss of key patent protections.Denmark’s Novo , once the poster-child for the growth in weight-loss treatments, said sales this year were likely to fall between 5% and 13%, despite the launch of its new Wegovy pill in the US. Its share price plummeted 18% on Wednesday morning, erasing all gains so far this year. In the past year the stock has lost nearly 50% of its value. Continue reading...

🔗 Citește articolul complet pe The Guardian World